Poxel Announces Its Participation at Investor and Scientific Conferences in September
06 September 2021 - 5:45PM
Business Wire
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced its participation at upcoming investor and scientific
conferences in September 2021.
- H.C. Wainwright 23rd Annual Global Investment Conference
Date: September 13-15, 2021 Thomas Kuhn, CEO, will present the
company, and Poxel management team members will be available for
one-on-one virtual meetings.
- The 11th International Meeting AMPK Date: September 26-30,
2021 Evian-les-Bains, France Poxel will deliver the following
oral presentations:
- “Characterization of a first-in-class direct AMPK activator,
PXL770, for NASH and other metabolic disorders: from Preclinical to
Clinical,” presented by Sophie Bozec, Senior Vice President,
R&D Pharmacology and Scientific Communication, Co-Founder
- “Potential therapeutic utility of direct AMPK Activators for
X-Linked Adrenoleukodystrophy,” presented by Pierre-Axel
Monternier, Senior Manager, Pharmacology
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing
innovative treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare disorders. Poxel has clinical and earlier-stage programs from
its adenosine monophosphate-activated protein kinase (AMPK)
activator and deuterated TZD platforms targeting chronic and rare
metabolic diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY). PXL770, a first-in-class direct AMPK activator,
has successfully completed a Phase 2a proof-of-concept trial for
the treatment of NASH, which met its objectives. In the rare
inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG (Imeglimin), Poxel’s first-in-class lead product that
targets mitochondrial dysfunction, has been approved for the
treatment of type 2 diabetes in Japan. With this approval, Poxel is
entitled to receive milestones, sales-based payments and royalties
from Sumitomo Dainippon Pharma. Poxel has a strategic partnership
with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South
Korea, Taiwan and nine other Southeast Asian countries. The Company
intends to generate further growth through strategic partnerships
and pipeline development. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210906005210/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78 Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com Investor relations /
Media - EU/US Trophic Communications Stephanie May or Valeria
Fisher poxel@trophic.eu +49 171 185 56 82 or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh or
Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Poxel (EU:POXEL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024